drugset / Trial / NCT00108875

Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer

NCT00108875 ↗

Phase 1/2 Unknown 70 enrolled Julius-Maximilians University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study evaluates the safety, the immunological response and the clinical outcome of a vaccination with survivin peptides for patients with advanced melanoma, pancreatic, colon and cervical carcinoma.

Timeline

Start
2003-04
Primary completion
—
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Survivin peptide vaccine Peptide — Subcutaneous